Genmab A/S (OTCMKTS:GNMSF – Get Free Report) was the target of a significant growth in short interest in August. As of August 31st, there was short interest totalling 206,200 shares, a growth of 11.1% from the August 15th total of 185,600 shares. Based on an average trading volume of 1,800 shares, the days-to-cover ratio is presently 114.6 days.
Genmab A/S Price Performance
Shares of OTCMKTS:GNMSF opened at $259.32 on Wednesday. The company has a market capitalization of $16.95 billion, a PE ratio of 21.47 and a beta of 1.07. The business has a fifty day moving average price of $268.44 and a 200-day moving average price of $277.33. Genmab A/S has a 1-year low of $241.09 and a 1-year high of $381.93.
Genmab A/S (OTCMKTS:GNMSF – Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported $3.13 earnings per share (EPS) for the quarter. The business had revenue of $779.50 million during the quarter. Genmab A/S had a net margin of 29.06% and a return on equity of 20.60%.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Further Reading
- Five stocks we like better than Genmab A/S
- What Are the FAANG Stocks and Are They Good Investments?
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- CD Calculator: Certificate of Deposit Calculator
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- What is the Shanghai Stock Exchange Composite Index?
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.